Table 2.
Multivariate analysis
| Adjusted OR (95% CI) | p value | |
| Positive CTPA (0.8%, 61 of 8026) | ||
| BMI < 24.9 kg/m2 (reference group) | 1.0 | |
| BMI 25 to 29.9 kg/m2 | 1.0 (0.4 to 2.5) | 0.94 |
| BMI 30 to 34.9 kg/m2 | 1.3 (0.5 to 3.0) | 0.61 |
| BMI 35 to 39.9 kg/m2 | 0.8 (0.3 to 2.4) | 0.70 |
| BMI ≥ 40 kg/m2 | 1.2 (0.3 to 4.3) | 0.77 |
| THA (reference group) | 1.0 | |
| TKA | 2.9 (1.3 to 6.5) | < 0.001 |
| UKA | 2.1 (0.5 to 8.3) | 0.28 |
| Aspirin (reference group) | 1.0 | |
| Enoxaparin | 0.5 (0.3 to 0.8) | 0.01 |
| ASA Grade 1 and 2 (reference group) | 1.0 | |
| ASA Grade 3 and 4 | 0.5 (0.2 to 1.2) | 0.11 |
| Consultant surgeon (reference group) | 1.0 | |
| Trainee surgeon | 0.9 (0.5 to 1.7) | 0.71 |
| Cementless implant (reference group) | 1.0 | |
| Cemented implant | 0.6 (0.1 to 2.5) | 0.47 |
| Hybrid implant | 3.5 (1.5 to 8.2) | < 0.001 |
| Female (reference group) | 1.0 | |
| Male | 1.0 (0.6 to 1.7) | 0.96 |
| Age per year | 1.0 (0.99 to 1.0) | 0.24 |
| Positive ultrasound (0.4%, 34 of 8026) | ||
| BMI < 24.9 kg/m2 (reference group) | 1.0 | |
| BMI 25 to 29.9 kg/m2 | 1.7 (0.5 to 6.3) | 0.42 |
| BMI 30 to 34.9 kg/m2 | 3.6 (1.0 to 12.6) | 0.046 |
| BMI 35 to 39.9 kg/m2 | 1.5 (0.3 to 7.7) | 0.62 |
| BMI ≥ 40 kg/m2 | 1.5 (0.2 to 14.9) | 0.74 |
| THA (reference group) | 1.0 | |
| TKA | 0.3 (0.1 to 0.7) | 0.03 |
| Aspirin (reference group) | 1.0 | |
| Enoxaparin | 0.8 (0.3 to 1.8) | 0.52 |
| ASA Grade 1 and 2 (reference group) | 1.0 | |
| ASA Grade 3 and 4 | 0.5 (0.2 to 1.6) | 0.26 |
| Consultant surgeon (reference group) | 1.0 | |
| Trainee surgeon | 0.7 (0.3 to 1.7) | 0.41 |
| Cementless implant (reference group) | 1.0 | |
| Cemented implant | 1.3 (0.4 to 3.9) | 0.66 |
| Hybrid implant | 0.5 (0.2 to 1.2) | 0.11 |
| Female (reference group) | 1.0 | |
| Male | 0.7 (0.4 to 1.5) | 0.41 |
| Age per year | 1.1 (1.0 to 1.1) | < 0.001 |